Manifold Bio focuses on creating precision biologics for the pharmaceutical industry. Their main product is an in vivo drug design platform, which allows for drug testing within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment. This is particularly beneficial for testing complex biologics, which are large molecule drugs derived from living organisms. Manifold Bio stands out from competitors by being the first to offer this in vivo drug design approach. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

SK Ventures

Triatomic Capital

FPV Ventures

Calibrate Ventures

Playground Global

TQ Ventures

GettyLab

Fifty Years

Horizon Ventures

Section 32 Allston Venture Fund

Biotechnology

Healthcare

Manifold Bio

Manifold Bio secues $15M in Series A funding.

Manifold Bio Secues $15M in Series A Funding

PALO ALTO, Calif.--(BUSINESS WIRE)--Playground Global, an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner. Ben focuses on identifying founders and companies that are revolutionizing engineered biology, building the future of emerging modality therapeutics development, and unlocking AI and ML workflows to refactor drug development. Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University. He became a Venture Associate a year later, and by 2022, he had led investments in two breakthrough biotech companies and was promoted to Venture Principal. In the last year, Ben has supported investments in Insamo (Board Observer and Lead Investor), Infinimmune (Board Director and Lead Seed Investor), Atomic AI (Board Observer and Lead Series A investor) and Amber Bio (Board Observer and Co-Led Seed Investment Round). He has also worked with Outpace Bio and Manifold Bio, where he is a Board Observer

Playground Global Promotes Benjamin Kim Phd To Partner

Manifold Bio, a Boston, MA-based protein therapeutics company, raised $40M in Series A funding. The round was led by Triatomic Capital with participation from Section 32, FPV Ventures, Horizons Ventures, Tencent, Playground Global, Fifty Years, and FAST. With this funding, Triatomic Capital founding partner Jeff Huber will join Manifold Bio’s board of directors. Huber was previously founder and CEO of Grail and co-founder of Google’s life sciences efforts

Manifold Bio Raises $40M In Series A Funding

Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent.

Horizons Ventures invested into manifold.bio in $40M on Jul 14th 22'.

In the creation of a new drug, there comes a point where you have to finally put the molecule in a real creature — one at a time — and see if it actually does what you think it does. Manifold Bio’s molecular machinery could let a hundred molecules be tested simultaneously in a single living system, potentially upending the whole process. The drug discovery space has advanced a lot in the last few years, first with fast and cheap gene transcription, then with CRISPR, then with AI-powered proteomics. You don’t have to know what all of those do, however, to understand that in the end, no matter how much they accelerate fundamental research, in vivo testing remains a major bottleneck

Manifold Bio’S Molecular ‘Barcodes’ Could Break Through Pharma’S In Vivo Bottleneck

Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has raised $40 million to develop a technology that could make testing cancer drugs more efficient.

Manifold Bio receives financing of $40M

Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Manifold Bio is raising $39,999,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gleb Kuznetsov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Manifold Bio

Allston Massachusetts Based Manifold Bio Is Raising $39,999,985.00 In New Equity Investment.

Manifold Bio raises seed round to bring massively multiplexed measurement to drug discovery.

Manifold Bio Raises Seed Round to Bring Massively Multiplexed Measurement to Drug Discovery

Designs precision biologics using in vivo methods

Manifold Bio

Designs precision biologics using in vivo methods

Manifold Bio

Designs precision biologics using in vivo methods

About

Simplify's Take

What believers are saying

What critics are saying

What makes Manifold Bio unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

Manifold Bio is Hiring for 0 Jobs on Simplify!